Literature DB >> 7611875

Immunogenicity of influenza and HSV-1 mixed antigen ISCOMs in mice.

H O Ghazi1, M Erturk, L M Stannard, M Faulkner, C W Potter, R Jennings.   

Abstract

Immunostimulating complexes (ISCOMs) were prepared with mixtures of antigens from influenza A virus (A/PR/8/34 or A/Sichuan/2/87) and herpes simplex virus type 1 (HSV-1), and were characterised by enzyme linked immunosorbent assay (ELISA) and electron microscopy using double-labelling immunogold techniques employing monoclonal antibodies to influenza or HSV-1 glycoproteins. The immunogenicity of the mixed antigen ISCOMs was evaluated in mice, following administration by the subcutaneous route, by measuring the total and subclass IgG antibody responses. Protection of these animals against challenge with live influenza A/Sichuan virus or live HSV-1, was compared with that induced by immunization with aqueous mixed antigen preparations. It was found that relatively high humoral responses to both influenza and HSV antigens, and increased levels of protection to both influenza and HSV viruses were elicited in mice receiving the mixed antigen ISCOM preparation compared to those observed in animals receiving the mixed aqueous subunit preparation. The findings also indicate that antigens from more than one virus can be used in an ISCOM formulation to produce immunity and protection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7611875     DOI: 10.1007/BF01315412

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  53 in total

1.  Soluble proteins incorporate into ISCOMs after covalent attachment of fatty acid.

Authors:  G Reid
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

2.  An experimental influenza subunit vaccine (iscom): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration.

Authors:  K Lövgren; H Kåberg; B Morein
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

3.  The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes.

Authors:  K Lövgren
Journal:  Scand J Immunol       Date:  1988-02       Impact factor: 3.487

4.  Local reactions of the saponin Quil A and a Quil A containing iscom measles vaccine after intramuscular injection of rats: a comparison with the effect of DPT-polio vaccine.

Authors:  G J Speijers; L H Danse; E C Beuvery; J J Strik; J G Vos
Journal:  Fundam Appl Toxicol       Date:  1988-04

5.  Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes.

Authors:  A J Morgan; S Finerty; K Lovgren; F T Scullion; B Morein
Journal:  J Gen Virol       Date:  1988-08       Impact factor: 3.891

6.  Canine distemper virus ISCOMs induce protection in harbour seals (Phoca vitulina) against phocid distemper but still allow subsequent infection with phocid distemper virus-1.

Authors:  I K Visser; E J Vedder; M W van de Bildt; C Orvell; T Barrett; A D Osterhaus
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

7.  Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice.

Authors:  E T Ben Ahmeida; G Gregoriadis; C W Potter; R Jennings
Journal:  Vaccine       Date:  1993-10       Impact factor: 3.641

8.  The infant rat as a model for assessment of the attenuation of human influenza viruses.

Authors:  M I Mahmud; R Jennings; C W Potter
Journal:  J Med Microbiol       Date:  1979-02       Impact factor: 2.472

9.  Control of infectious bovine rhinotracheitis in calves with a BHV-1 subunit-ISCOM vaccine.

Authors:  M Trudel; G Boulay; C Séguin; F Nadon; G Lussier
Journal:  Vaccine       Date:  1988-12       Impact factor: 3.641

10.  Antibody responses and protection in mice immunized with herpes simplex virus type 1 antigen immune-stimulating complex preparations.

Authors:  M Ertürk; R Jennings; D Hockley; C W Potter
Journal:  J Gen Virol       Date:  1989-08       Impact factor: 3.891

View more
  1 in total

Review 1.  Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.

Authors:  Blaise Corthésy; Gilles Bioley
Journal:  Front Immunol       Date:  2018-03-07       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.